Notice2022-28571
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 4, 2023
Issuing agencies
Defense Department
Abstract
The DoD is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel (UF BAP) will take place.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 2 (Wednesday, January 4, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 2 (Wednesday, January 4, 2023)]
[Notices]
[Page 348]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-28571]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal
Advisory Committee Meeting
AGENCY: Under Secretary of Defense for Personnel and Readiness,
Department of Defense (DoD).
ACTION: Notice of Federal Advisory Committee meeting.
-----------------------------------------------------------------------
SUMMARY: The DoD is publishing this notice to announce that the
following Federal Advisory Committee meeting of the Uniform Formulary
Beneficiary Advisory Panel (UF BAP) will take place.
DATES: Open to the public Wednesday, January 4, 2023, 10 a.m.-1 p.m.
(Eastern Standard Time).
ADDRESSES: The meeting will be held telephonically or via conference
call. The phone number for the remote access on January 4, 2023 is:
CONUS: 1-800-369-2046; OCONUS: 1-203-827-7030; PARTICIPANT CODE:
8546285.
These numbers and the dial-in instructions will also be posted on
the UF BAP website at: <a href="https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP">https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP</a>.
FOR FURTHER INFORMATION CONTACT: Designated Federal Officer (DFO)
Colonel Paul J. Hoerner, USAF, 703-681-2890 (voice), <a href="/cdn-cgi/l/email-protection#3b5f535a155558491551160d1556594315595a4b495e4a4e5e484f487b535e5a574f5315565257"><span class="__cf_email__" data-cfemail="a3c7cbc28dcdc0d18dc98e958dcec1db8dc1c2d3d1c6d2d6c6d0d7d0e3cbc6c2cfd7cb8dcecacf">[email protected]</span></a> (email). Mailing address is 7700 Arlington
Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: <a href="https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP">https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP</a>. The most up-to-date changes to the meeting
agenda can be found on the website.
SUPPLEMENTARY INFORMATION: This meeting is being held under the
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5
U.S.C., Appendix, as amended), the Government in the Sunshine Act of
1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
Due to circumstances beyond the control of the Designated Federal
Officer, the Uniform Formulary Beneficiary Advisory Panel was unable to
provide public notification required by 41 CFR 102-3.150(a) concerning
its January 4, 2023, meeting. Accordingly, the Advisory Committee
Management Officer for the Department of Defense, pursuant to 41 CFR
102-3.150(b), waives the 15-calendar day notification requirement.
Purpose of the Meeting: The Panel will review and comment on
recommendations made to the Director, Defense Health Agency, by the
Pharmacy and Therapeutics Committee, regarding the Uniform Formulary.
Agenda
1. 10:00 a.m.-10:10 a.m. Sign In for UF BAP members
2. 10:10 a.m.-10:40 a.m. Welcome and Opening Remarks
a. Welcome, Opening Remarks, and Introduction of UF BAP Members by
Col Paul J. Hoerner, DFO, UF BAP
b. Public Written Comments by Col Paul J. Hoerner, DFO, UF BAP
c. Opening Remarks by UF BAP Co-Chair Senior Chief Petty Officer
Jon R. Ostrowski, Non-Commissioned Officers Association
d. Introductory Remarks by Dr Edward Vonberg, Chief, Formulary
Management Branch
3. 10:40 a.m.-11:45 a.m. Scheduled Therapeutic Class Reviews
a. Atopy--Oral Janus Kinase (JAK) Inhibitors
b. Hematological Agents--Red Blood Cell (RBC) Stimulants-
Erythropoietin Subclass
4. 11:45 a.m.-12:30 p.m. Newly Approved Drugs Review
5. 12:30 p.m.-12:45 p.m. Pertinent Utilization Management Issues
* Note that UF BAP discussion and vote will follow each section
6. 12:45 p.m.-1:00 p.m. Closing remarks
a. Closing Remarks by UF BAP Co-Chair Senior Chief Petty Officer
Jon R. Ostrowski
b. Closing Remarks by Col Paul J. Hoerner, DFO, UF BAP
Meeting Accessibility: Pursuant to section 10(a)(1) of the FACA and
41 CFR 102-3.140 through 102-3.165, and subject to the availability of
phone lines, this meeting is open to the public. Telephone lines are
limited and available to the first 220 people dialing in. There will be
220 lines total: 200 domestic and 20 international, including leader
lines.
Written Statements: Pursuant to 41 CFR 102-3.10, and section
10(a)(3) of FACA, interested persons or organizations may submit
written statements to the UF BAP about its mission and/or the agenda to
be addressed in this public meeting. Written statements should be
submitted to the UF BAP's DFO. The DFO's contact information can be
found in the FOR FURTHER INFORMATION CONTACT section of this notice.
Written comments or statements must be received by the UF BAP's DFO at
least five (5) calendar days prior to the meeting so they may be made
available to the UF BAP for its consideration prior to the meeting. The
DFO will review all submitted written statements and provide copies to
UF BAP.
Dated: December 29, 2022.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2022-28571 Filed 1-3-23; 8:45 am]
BILLING CODE 5001-06-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 4, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.